eLife (Apr 2018)
Donated chemical probes for open science
- Susanne Müller,
- Suzanne Ackloo,
- Cheryl H Arrowsmith,
- Marcus Bauser,
- Jeremy L Baryza,
- Julian Blagg,
- Jark Böttcher,
- Chas Bountra,
- Peter J Brown,
- Mark E Bunnage,
- Adrian J Carter,
- David Damerell,
- Volker Dötsch,
- David H Drewry,
- Aled M Edwards,
- James Edwards,
- Jon M Elkins,
- Christian Fischer,
- Stephen V Frye,
- Andreas Gollner,
- Charles E Grimshaw,
- Adriaan IJzerman,
- Thomas Hanke,
- Ingo V Hartung,
- Steve Hitchcock,
- Trevor Howe,
- Terry V Hughes,
- Stefan Laufer,
- Volkhart MJ Li,
- Spiros Liras,
- Brian D Marsden,
- Hisanori Matsui,
- John Mathias,
- Ronan C O'Hagan,
- Dafydd R Owen,
- Vineet Pande,
- Daniel Rauh,
- Saul H Rosenberg,
- Bryan L Roth,
- Natalie S Schneider,
- Cora Scholten,
- Kumar Singh Saikatendu,
- Anton Simeonov,
- Masayuki Takizawa,
- Chris Tse,
- Paul R Thompson,
- Daniel K Treiber,
- Amélia YI Viana,
- Carrow I Wells,
- Timothy M Willson,
- William J Zuercher,
- Stefan Knapp,
- Anke Mueller-Fahrnow
Affiliations
- Susanne Müller
- ORCiD
- Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt, Frankfurt am Main, Germany
- Suzanne Ackloo
- Structural Genomics Consortium, University of Toronto, Toronto, Canada
- Cheryl H Arrowsmith
- Department of Medical Biophysics, University of Toronto, Toronto, Canada
- Marcus Bauser
- Drug Discovery Pharmaceuticals, Bayer AG, Berlin, Germany
- Jeremy L Baryza
- Vertex Pharmaceuticals, Boston, United States
- Julian Blagg
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom
- Jark Böttcher
- Discovery Research, Boehringer Ingelheim, Vienna, Austria
- Chas Bountra
- Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Peter J Brown
- Structural Genomics Consortium, University of Toronto, Toronto, Canada
- Mark E Bunnage
- Vertex Pharmaceuticals, Boston, United States
- Adrian J Carter
- Discovery Research, Boehringer Ingelheim, Ingelheim am Rhein, Germany
- David Damerell
- Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Volker Dötsch
- ORCiD
- Institute of Biophysical Chemistry, Goethe-University, Frankfurt am Main, Germany; Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt am Main, Germany
- David H Drewry
- Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, United States
- Aled M Edwards
- Structural Genomics Consortium, University of Toronto, Toronto, Canada
- James Edwards
- Janssen Pharmaceutical Research and Development LLC, Spring House, United States
- Jon M Elkins
- ORCiD
- Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Christian Fischer
- Merck & Co., Inc., Boston, United States
- Stephen V Frye
- Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, United States
- Andreas Gollner
- Discovery Research, Boehringer Ingelheim, Biberach an der Riss, Germany
- Charles E Grimshaw
- ORCiD
- Ched Grimshaw Consulting, LLC, Poway, United States
- Adriaan IJzerman
- Division of Medicinal Chemistry, Leiden University, Leiden, Netherlands
- Thomas Hanke
- ORCiD
- Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt, Frankfurt am Main, Germany
- Ingo V Hartung
- Drug Discovery Pharmaceuticals, Bayer AG, Berlin, Germany
- Steve Hitchcock
- Takeda California Inc., San Diego, United States
- Trevor Howe
- J&J Innovation Centre, London, United Kingdom
- Terry V Hughes
- J&J Innovation Centre, London, United Kingdom
- Stefan Laufer
- Department of Pharmaceutical Chemistry, Eberhard Karls Universität Tübingen, Tübingen, Germany
- Volkhart MJ Li
- Drug Discovery Pharmaceuticals, Bayer AG, Wuppertal, Germany
- Spiros Liras
- Worldwide Medicinal Chemistry, Pfizer, Cambridge, United States
- Brian D Marsden
- Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
- Hisanori Matsui
- Takeda Pharmaceutical Company Ltd, Fujisawa, Japan
- John Mathias
- Worldwide Medicinal Chemistry, Pfizer, Cambridge, United States
- Ronan C O'Hagan
- Merck & Co., Inc., Boston, United States
- Dafydd R Owen
- Worldwide Medicinal Chemistry, Pfizer, Cambridge, United States
- Vineet Pande
- Discovery Sciences, Janssen-Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium
- Daniel Rauh
- Fakultät für Chemie und Chemische Biologie, Technische Universität Dortmund, Dortmund, Germany
- Saul H Rosenberg
- AbbVie, North Chicago, United States
- Bryan L Roth
- The National Institute of Mental Health Psychoactive Active Drug Screening Program, University of North Carolina Chapel Hill School of Medicine, Chapel Hill, United States
- Natalie S Schneider
- Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt, Frankfurt am Main, Germany
- Cora Scholten
- Drug Discovery Pharmaceuticals, Bayer AG, Berlin, Germany
- Kumar Singh Saikatendu
- Takeda California Inc., San Diego, United States
- Anton Simeonov
- National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, United States
- Masayuki Takizawa
- Takeda Pharmaceutical Company Ltd., Fujisawa, Japan
- Chris Tse
- AbbVie, North Chicago, United States
- Paul R Thompson
- Department of Biochemistry and Pharmacology, University of Massachusetts Medical School, Worcester, United States
- Daniel K Treiber
- Eurofins DiscoverX, Sane Diego, United States
- Amélia YI Viana
- Discovery Research, Boehringer Ingelheim, Ingelheim am Rhein, Germany
- Carrow I Wells
- Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, United States
- Timothy M Willson
- Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, United States
- William J Zuercher
- Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, United States
- Stefan Knapp
- Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt, Frankfurt am Main, Germany
- Anke Mueller-Fahrnow
- Drug Discovery Pharmaceuticals, Bayer AG, Berlin, Germany
- DOI
- https://doi.org/10.7554/eLife.34311
- Journal volume & issue
-
Vol. 7
Abstract
Potent, selective and broadly characterized small molecule modulators of protein function (chemical probes) are powerful research reagents. The pharmaceutical industry has generated many high-quality chemical probes and several of these have been made available to academia. However, probe-associated data and control compounds, such as inactive structurally related molecules and their associated data, are generally not accessible. The lack of data and guidance makes it difficult for researchers to decide which chemical tools to choose. Several pharmaceutical companies (AbbVie, Bayer, Boehringer Ingelheim, Janssen, MSD, Pfizer, and Takeda) have therefore entered into a pre-competitive collaboration to make available a large number of innovative high-quality probes, including all probe-associated data, control compounds and recommendations on use (https://openscienceprobes.sgc-frankfurt.de/). Here we describe the chemical tools and target-related knowledge that have been made available, and encourage others to join the project.
Keywords
